pipette
ESEspañol

Mavacamten and Obstructive Hypertrophic Cardiomyopathy in Teens

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
To the Editor: In the Study of Mavacamten in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (SCOUT-HCM), conducted by Rossano et al. (July 23 issue), 1 two patients in the mavacamten group had serious adverse cardiac events, including one patient with episodes of syncope that were deemed by the investigator to be related to mavacamten.
Limitation the authors admit
It would have been helpful to determine the activity of the cytochrome P450 (CYP) enzyme CYP2C19 in that patient.

Appeared: Friday, October 23. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmc2611023